Nyah Phengsitthy - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock Nyah Phengsitthy's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
Nyah Phengsitthy

Nyah Phengsitthy

Verified

Health Reporter, Bloomberg Law

Washington

Final Covers

Human rightsHuman interest and GenderSocial justice

Doesn’t Cover

N/A - everything will be considered

Journalist Type

-

Seniority Positions

-

Industries

Medium Formats

-

Content

Total articles 475

  • Novartis, FDA Battle Over Generic Drug Labeling in DC Circuit

    By Nyah Phengsitthy Verified| Bloomberg Law Verified A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of its heart failure drug, pressing both the manufacturer and agency on the accuracy of the drug labels. The US Court of Appeals for the District of Columbia Circuit tried to drill down into Novartis’s reasoning for opposing the Food and Drug Administration’s approval of MSN Laboratories’ generic Entresto.

    By Nyah Phengsitthy Verified · Bloomberg Law

    Apr. 17, 2025

  • Trump Drug Pricing Order Spurs Doubts With Staff Cuts, Tariffs

    By Celine Castronuovo Verified, Nyah Phengsitthy Verified| Bloomberg Law Verified President Donald Trump’s executive order to lower prescription drug costs is filled with actions that policy analysts and patient groups say will reward the pharmaceutical industry while doing little to reduce health-care spending nationwide. The order, which Trump signed April 15, directs the health secretary to work with Congress on policy that could give certain medications more time on the market before they’re subject to Medicare price negotiations.

    By Celine Castronuovo Verified, Nyah Phengsitthy Verified · Bloomberg Law

    Apr. 17, 2025

  • Novartis, FDA Battle Over Generic Drug Labeling in DC Circuit

    By Nyah Phengsitthy Verified| Bloomberg Law Verified A three-judge panel wrestled Thursday with Novartis AG’s challenge against the FDA over its approval of a generic version of its heart failure drug, pressing both the manufacturer and agency on the accuracy of the drug labels. The US Court of Appeals for the District of Columbia Circuit tried to drill down into Novartis’s reasoning for opposing the Food and Drug Administration’s approval of MSN Laboratories’ generic Entresto.

    By Nyah Phengsitthy Verified · Bloomberg Law

    Apr. 17, 2025

As seen in

Company Info

Bloomberg Law

Bloomberg Law is a legal research and workflow solutions platform under Bloomberg L.P. It provides AI-driven tools and data analytics tailored for legal professionals. The platform offers a comprehensive database for case law, statutes, and legal analysis, available through a fixed-price subscription model that allows unlimited access. The services include AI-powered contract solutions for drafting and analysis, as well as a legal project management platform called Dashboard Legal, which enhances task tracking and document management. Bloomberg Law also features specialized content inherited from the Bureau of National Affairs, including niche publications and real-time regulatory updates. By integrating legal research with Bloomberg's financial data ecosystem, the platform delivers predictive analytics and document automation, aiming to streamline workflows for law firms, corporate legal departments, and government agencies.

Arlington, Virginia, United States

+1 888-560-2529

Founded: 1981